| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 7369- | HibSad, | Components in aqueous Hibiscus rosa-sinensis flower extract inhibit in vitro melanoma cell growth |
| - | in-vitro, | Melanoma, | B16-BL6 | - | in-vitro, | Nor, | LA25 |
| 7365- | HibSad, | Insight into the molecular evidence supporting the remarkable chemotherapeutic potential of Hibiscus sabdariffa L |
| - | Review, | Var, | NA |
| 7363- | HibSad, | Chemopreventive properties of Hibiscus sabdariffa L. on human gastric carcinoma cells through apoptosis induction and JNK/p38 MAPK signaling activation |
| - | in-vitro, | GC, | NA |
| 7356- | HibSad, | Hibiscus flower extract selectively induces apoptosis in breast cancer cells and positively interacts with common chemotherapeutics |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 7347- | Hne, | Study of potent cytotoxic activity of Helleborus cyclophyllus Boiss against a human adenocarcinoma cell line |
| - | in-vitro, | Lung, | A549 |
| 7343- | Hne, | Comparative Evaluation of the Potential Antitumor of Helleborus purpurascens in Skin and Breast Cancer |
| - | in-vitro, | Melanoma, | A431 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HaCaT | - | in-vitro, | Nor, | JB6 |
| 7340- | Hne, | Differential cytotoxic properties of Helleborus niger L. on tumour and immunocompetent cells |
| - | in-vitro, | AML, | NA |
| 2875- | HNK, | Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | SCC, | H226 |
| 2879- | HNK, | Honokiol Inhibits Lung Tumorigenesis through Inhibition of Mitochondrial Function |
| - | in-vitro, | Lung, | H226 | - | in-vivo, | NA, | NA |
| 2865- | HNK, | Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma |
| - | in-vitro, | MB, | DAOY | - | vitro+vivo, | NA, | NA |
| 2864- | HNK, | Honokiol: A Review of Its Anticancer Potential and Mechanisms |
| - | Review, | Var, | NA |
| 2891- | HNK, | Honokiol, an Active Compound of Magnolia Plant, Inhibits Growth, and Progression of Cancers of Different Organs |
| - | Review, | Var, | NA |
| 2892- | HNK, | Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H385 | - | in-vitro, | Nor, | BEAS-2B |
| 2895- | HNK, | Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity |
| - | in-vitro, | Lung, | PC9 |
| 2073- | HNK, | Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo |
| - | in-vitro, | OS, | U2OS | - | in-vivo, | NA, | NA |
| 7371- | HOO, | Phytochemical characterization of peanut oil and its ozonized form to explore biological activities in vitro |
| - | in-vitro, | Colon, | NA |
| 7626- | HPT, | Rad, | Dynamics of chromosomal aberrations, induction of apoptosis, BRCA2 degradation and sensitization to radiation by hyperthermia |
| - | in-vitro, | Var, | NA |
| 7542- | HT, | Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B | - | in-vitro, | Nor, | RWPE-1 |
| 4637- | HT, | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells |
| - | in-vitro, | Nor, | RWPE-1 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | 22Rv1 | - | in-vitro, | Pca, | PC3 |
| 4638- | HT, | Hydroxytyrosol induces apoptosis in human colon cancer cells through ROS generation |
| - | in-vitro, | CRC, | DLD1 | - | NA, | NA, | 1- |
| 4639- | HT, | Hydroxytyrosol Induces Apoptosis, Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 4640- | HT, | The anti-cancer potential of hydroxytyrosol |
| - | Review, | Var, | NA |
| 7568- | HYP, | PacT, | Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7553- | HYP, | Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7596- | I3C, | Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent |
| - | in-vitro, | BC, | NA |
| 7607- | I3C, | Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line |
| - | in-vitro, | AML, | THP1 |
| 7610- | I3C, | Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | Nor, | HBL-100 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 7612- | I3C, | Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells |
| - | in-vitro, | Nor, | MCF10 |
| 7585- | I3C, | Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells |
| - | in-vitro, | BC, | NA |
| 7801- | IBC, | Isobavachalcone as an Active Membrane Perturbing Agent and Inhibitor of ABCB1 Multidrug Transporter |
| - | in-vitro, | CRC, | HT-29 |
| 7807- | IBC, | Isobavachalcone exerts anti‑proliferative and pro‑apoptotic effects on human liver cancer cells by targeting the ERKs/RSK2 signaling pathway |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | Hep3B | - | in-vitro, | Nor, | L02 |
| 7818- | IBC, | Isobavachalcone, a chalcone constituent of Angelica keiskei, induces apoptosis in neuroblastoma |
| - | in-vitro, | neuroblastoma, | NA |
| 7631- | Ins, | IP6, | Broad Spectrum Anticancer Activity of Myo-Inositol and Inositol Hexakisphosphate |
| - | Review, | Var, | NA |
| 7674- | iod, | Molecular iodine induces caspase-independent apoptosis in human breast carcinoma cells involving the mitochondria-mediated pathway |
| - | in-vitro, | BC, | NA |
| 7678- | iod, | Signaling pathways involved in the antiproliferative effect of molecular iodine in normal and tumoral breast cells: evidence that 6-iodolactone mediates apoptotic effects |
| - | in-vitro, | Nor, | MCF12A | - | in-vitro, | BC, | MCF7 |
| 7719- | IP6, | Effect of inositol hexaphosphate (IP(6)) on human normal and leukaemic haematopoietic cells |
| - | in-vitro, | CML, | NA |
| 7690- | IP6, | Ins, | Inositol Hexaphosphate (IP6) and Colon Cancer: From Concepts and First Experiments to Clinical Application |
| - | Review, | Colon, | NA |
| 7699- | IP6, | IP6: From Seeds to Science—A Natural Compound’s Path to Clinical Promise |
| - | Review, | Var, | NA |
| 7748- | ISL, | GEM, | Isoliquiritigenin combined with gemcitabine inhibited lung cancer by suppressing JAK2/STAT3 signaling via lncRNA-p21/miRNA-4534 axis |
| - | in-vitro, | Lung, | NA |
| 7781- | ISL, | Perspectives on the Role of Isoliquiritigenin in Cancer |
| - | Review, | Var, | NA |
| 7787- | ISL, | Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling |
| - | in-vitro, | BC, | NA |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 7732- | isoFl, | Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity |
| - | Review, | Var, | NA |
| 7856- | isoO, | Isoorientin induces the apoptosis and cell cycle arrest of A549 human lung cancer cells via the ROS‑regulated MAPK, STAT3 and NF‑κB signaling pathways |
| - | in-vitro, | Lung, | A549 |
| 7854- | isoO, | Isoorientin induces apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cancer cells |
| - | in-vitro, | Liver, | HepG2 |
| 7866- | isoO, | Orientin and Cancer Suppression: Molecular Mechanisms and Synergistic Effects |
| - | Review, | Var, | NA |
| 7810- | ISQ, | Isoquercitrin Inhibits Lung Cancer Cell Growth Through Triggering Pyroptosis and Ferroptosis |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7795- | ISQ, | The Flavonol Isoquercitrin Promotes Mitochondrial-Dependent Apoptosis in SK-Mel-2 Melanoma Cell via the PI3K/AKT/mTOR Pathway |
| - | in-vitro, | Melanoma, | SK-MEL-28 | - | in-vitro, | Nor, | HaCaT |
| 7792- | ISQ, | Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW48 | - | in-vitro, | CRC, | DLD1 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | IEC-18 |
| 9191- | ITCs, | AITC, | BITC, | PEITC, | SFN | Molecular Targets of Isothiocyanates in Cancer: Recent Advances |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1110 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid